Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic, NCI Collaborating on Mitochondrial Genome Characterization in Cancer Cell Lines

NEW YORK (GenomeWeb News) – The National Cancer Institute has approved a proposal by the genetic analysis and services company Transgenomic to do mutational analysis and sequencing on mitochondrial genes in the NCI 60 panel of cancer cell lines, the company announced today.
 
The collaboration between NCI and Omaha, Neb.-based Transgenomic is expected to be the first comprehensive evaluation of the mitochondrial genome in this cell panel, which has been used to test compounds in NCI’s pharmacological database.
 
Transgenomic said the work may provide clues about early disease states and insights into some cancer treatments and diagnostics, since mitochondrial damage can be an early warning sign for some types of cancer.
 
“This collaboration makes it possible to test whether in vitro responses to anti-cancer agents are linked to alterations in the mitochondrial genome and can be detected with our sensitive mutation detection technology,” Transgenomic Chief Scientific Officer Eric Kaldjian said in a statement.
 

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.